Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281 · cited 1×
“Generation of mice deficient in the mdr1a ( abcb1a ) and mdr1b ( abcb1b ) genes, or both, has provided a valuable tool for the assessment of the contribution of Pgp to drug disposition in vivo”
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“Pgp transports drugs that are central to most chemotherapeutic regimens, including (but certainly not limited to) vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes (for a comprehensive review see Ref”
BackgroundSelf-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“As overexpression of MRP3, MRP6 or MRP7 has not been detected in resistant cell lines, their involvement in clinically relevant drug resistance or the physiological defence of tissues against xenobiotic compounds seems limite”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748 · cited 1×
“The human genome contains 48 genes that encode ABC transporters, which have been divided into seven subfamilies labelled A–”
BackgroundTsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386 · cited 1×
“Transported substrates include cytotoxic drugs, toxins and carcinogens found in food products, as well as endogenous compound”
BackgroundMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M. (2001) · Genome Research · doi:10.1101/gr.gr-1649r · Cited by 1,113
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Self-citationCordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062 · cited 1×
“Pgp is normally expressed in the transport epithelium of the liver, kidney and gastrointestinal tract, at pharmacological barrier sites, in adult stem cells and in assorted cells of the immune syste”
BackgroundKim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
Gros, P., Croop, J., & Housman, D. (1986) · Cell · doi:10.1016/0092-8674(86)90594-5 · Cited by 1,031
Strautnieks, S. S., Bull, L. N., Knisely, A. S., Kocoshis, S. A., Dahl, N., Arnell, H., Sokal, E., Dahan, K., Childs, S., Ling, V., et al. (1998) · Nature Genetics · doi:10.1038/3034 · Cited by 995 · cited 1×
“Mutations in the genes encoding these proteins cause various forms of progressive familial intrahepatic cholestasi”
BackgroundThe Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver
Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A. F., & Meier, P. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.10046 · Cited by 939 · cited 1×
“The two additional members of the ABCB subfamily implicated in drug resistance are normally expressed in the liver: ABCB11 ('sister of Pgp”
BackgroundMiyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 929
Allikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 916
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., & Borst, P. (1997) · PubMed · Cited by 882
van Helvoort, A., Smith, A. J., Sprong, H., Fritzsche, I., Schinkel, A. H., Borst, P., & van Meer, G. (1996) · Cell · doi:10.1016/s0092-8674(00)81370-7 · Cited by 855 · cited 1×
“), a bile salt transporter, and ABCB4 (MDR3), a phosphatidylcholine flippas”
BackgroundThe orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene
Paulusma, C. C., Bosma, P. J., Zaman, G. J. R., Bakker, C. T. M., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P., & Elferink, R. P. J. O. (1996) · Science · doi:10.1126/science.271.5252.1126 · Cited by 822 · cited 1×
“The phenotype associated with mutations in the gene encoding MRP2 is called Dubin–Johnson syndrome, a condition in which the lack of hepatobiliary transport of non-bile salt organic anions results in conjugated hyperbilirubinaemi”
BackgroundThe Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817 · cited 1×
“The role of ABC transporters in clinical anticancer resistance has been difficult to asses”
BackgroundA Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
Active outward transport of daunomycin in resistant ehrlich ascites tumor cells
Danø, K. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90191-0 · Cited by 723 · cited 1×
“In the first study that described MDR, it was also shown that sensitization of resistant cells was achievable with modulators that prevent the export of cytotoxic drug”
BackgroundCui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676
Gerlach, J. H., Endicott, J. A., Juranka, P. F., Henderson, G., Sarangi, F., Deuchars, K. L., & Ling, V. (1986) · Nature · doi:10.1038/324485a0 · Cited by 667
MRP3, an organic anion transporter able to transport anti-cancer drugs
Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M. L., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6914 · Cited by 645
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638
Sarkadi, B., Price, E. M., Boucher, R. C., Germann, U. A., & Scarborough, G. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42909-2 · Cited by 632
The MRP family of drug efflux pumps
Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 614
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1989) · Journal of Histochemistry & Cytochemistry · doi:10.1177/37.2.2463300 · Cited by 604
Self-citationPhosphatidylcholine translocase: A physiological role for the mdr2 gene
Ruetz, S. (1994) · Cell · doi:10.1016/0092-8674(94)90446-4 · Cited by 599 · cited 1×
“), a bile salt transporter, and ABCB4 (MDR3), a phosphatidylcholine flippas”
BackgroundMRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
Schuetz, J. D., Connelly, M. C., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A., & Fridland, A. (1999) · Nature Medicine · doi:10.1038/12487 · Cited by 575
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573
Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum
Le Saux, O., Urban, Z., Tschuch, C., Csiszar, K., Bacchelli, B., Quaglino, D., Pasquali-Ronchetti, I., Pope, F. M., Richards, A., Terry, S., et al. (2000) · Nature Genetics · doi:10.1038/76102 · Cited by 540
Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Self-citationRao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., & Piwnica-Worms, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3900 · Cited by 531
Hyafil, F., Pauwels-Vergely, C., Vignaud, P. D., & Grand‐Perret, T. (1993) · PubMed · Cited by 525
König, J., Rost, D., Cui, Y., & Keppler, D. (1999) · Hepatology · doi:10.1002/hep.510290404 · Cited by 504 · cited 1×
“Substrates of MRP3 include anticancer drugs and some bile acid species, as well as several glucuronate, sulphate and GSH conjugate”
BackgroundZaman, G. J., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R. P., Baas, F., & Borst, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7690 · Cited by 498
Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W., & Greenberger, L. M. (2000) · PubMed · Cited by 487
Haimeur, A., Conseil, G., Deeley, R., & Cole, S. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489199 · Cited by 485
HIV-1 Protease Inhibitors Are Substrates for the MDR 1 Multidrug Transporter
Lee, C. G. L., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K.-T., Ambudkar, S. V., Pastan, I., & Dey, S. (1998) · Biochemistry · doi:10.1021/bi972709x · Cited by 477
Self-citationShen, D. W., Cardarelli, C., Hwang, J., Cornwell, M., Richert, N., Ishii, S., Pastan, I., & Gottesman, M. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57466-x · Cited by 461
Self-citationThe physiological function of drug-transporting P-glycoproteins
Schinkel, A. H. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0068 · Cited by 458 · cited 1×
“The AUC (area under the plasma concentration versus time curve) of orally administered taxol was found to be significantly higher in the double knockout mice, indicating that Pgp expression at the intestinal lumen can limit oral drug bioavailabilit”
BackgroundAntifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., Scheper, R. J., Borst, P., Pinedo, H. M., & Jansen, G. (1999) · PubMed · Cited by 442
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434 · cited 1×
“As an example, a meta-analysis of 31 breast cancer trials showed a threefold reduction in response to chemotherapy among tumours expressing Pgp after treatmen”
MethodDombrowski, S. M., Desai, S. Y., Marroni, M., Cucullo, L., Goodrich, K., Bingaman, W., Mayberg, M. R., Bengez, L., & Janigro, D. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.12301.x · Cited by 426
Jonker, J. W., Merino, G., Musters, S., van Herwaarden, A. E., Bolscher, E., Wagenaar, E., Mesman, E., Dale, T. C., & Schinkel, A. H. (2005) · Nature Medicine · doi:10.1038/nm1186 · Cited by 423
List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 419 · cited 1×
“Despite these problems, a randomized Phase III clinical trial showed the benefit of addition of cyclosporine to treatment with cytarabine and daunorubicin in patients with poor-risk AM”
BackgroundLocalisation of breast cancer resistance protein in microvessel endothelium of human brain
Cooray, H. C., Blackmore, C. G., Maskell, L., & Barrand, M. A. (2002) · NeuroReport · doi:10.1097/00001756-200211150-00014 · Cited by 419
Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy
Leggas, M., Adachi, M., Scheffer, G. L., Sun, D., Wielinga, P., Du, G., Mercer, K. E., Zhuang, Y., Panetta, J. C., Johnston, B., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7612-7621.2004 · Cited by 414
Structural, mechanistic and clinical aspects of MRP1
Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412 · cited 1×
“ABCC1 (widely known as MRP1) is expressed in a wide range of tissues, clinical tumour”
BackgroundTransport of Cyclic Nucleotides and Estradiol 17-β-d-Glucuronide by Multidrug Resistance Protein 4
Chen, Z.-S., Lee, K., & Kruh, G. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104833200 · Cited by 396
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Reid, G., Wielinga, P., Zelcer, N., de Haas, M., van Deemter, L., Wijnholds, J., Balzarini, J., & Borst, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.1094 · Cited by 368
Baer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Mirski, S. E. L., Gerlach, J. H., & Cole, S. P. C. (1987) · PubMed · Cited by 351
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Robey, R. W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P., & Bates, S. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3298 · Cited by 350
Robey, R. W., Medina-Pérez, W. Y., Nishiyama, K., Lahusen, T. J., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D., & Bates, S. E. (2001) · PubMed · Cited by 341
Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T., & Hori, R. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10423-0 · Cited by 337
Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain
Bakos, É., Evers, R., Szakács, G., Tusnády, G. E., Welker, E., Szabó, K., de Haas, M., van Deemter, L., Borst, P., Váradi, A., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.32167 · Cited by 326 · cited 1×
“The four remaining members ( ABCC4 , ABCC5 , ABCC11 and ABCC12 ) lack the N-terminal TMD (but not the linker region, which is characteristic of the subfamil”
BackgroundSelf-citationExpression of members of the multidrug resistance protein family in human term placenta
St-Pierre, M. V., Serrano, M. A., Macias, R. I. R., Dubs, U., Hoechli, M., Lauper, U., Meier, P. J., & Marin, J. J. G. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1495 · Cited by 325
Rius, M., Nies, A. T., Hummel-Eisenbeiss, J., Jedlitschky, G., & Keppler, D. (2003) · Hepatology · doi:10.1053/jhep.2003.50331 · Cited by 324
Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic Anions
Bakos, É., Evers, R., Sinkó, E., Váradi, A., Borst, P., & Sarkadi, B. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26477-4 · Cited by 322
Functional Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect Cells
Özvegy, C., Litman, T., Szakács, G., Nagy, Z., Bates, S., Váradi, A., & Sarkadi, B. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5130 · Cited by 319
Self-citationChen, Z., Lee, K., WALTHER, S. E., Raftogianis, R. B., Kuwano, M., Zeng, H., & Kruh, G. D. (2002) · PubMed · Cited by 316
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Mechetner, E. B., & Roninson, I. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5824 · Cited by 316
Multiple physiological functions for multidrug transporter P-glycoprotein?
JOHNSTONE, R., RUEFLI, A., & SMYTH, M. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01493-0 · Cited by 309 · cited 1×
“Recent observations support the possibility that Pgp can promote cell survival by efflux-independent pathways, including the inhibition of caspase-dependent apoptosi”
BackgroundReversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
de Bruin, M., Miyake, K., Litman, T., Robey, R., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298
Multidrug Resistance Reversal Agents
Robert, J., & Jarry, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030183a · Cited by 292
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281 · cited 1×
“Pgp can thereby reduce the efficacy of agents targeted to the central nervous system (CNS) to treat epilepsy, central infections (such as HIV) or brain tumour”
BackgroundIdentification of a sister gene to P-glycoprotein.
Childs, S. J., Yeh, R. L., Georges, E., & Ling, V. W. T. (1995) · PubMed · Cited by 272
The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts
Chandra, P., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026420.79421.8f · Cited by 266
Tissue Distribution and Induction of Human Multidrug Resistant Protein 3
Scheffer, G. L., Kool, M., de Haas, M., de Vree, J. M. L., Pijnenborg, A. C. L. M., Bosman, D. K., Oude Elferink, R. P. J., van der Valk, P., Borst, P., & Scheper, R. J. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780411 · Cited by 266
Belinsky, M. G., Chen, Z., Shchaveleva, I., Zeng, H., & Kruh, G. D. (2002) · PubMed · Cited by 262
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)
Zelcer, N., Saeki, T., Reid, G., Beijnen, J. H., & Borst, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107041200 · Cited by 258
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
Benet, L. Z., Cummins, C. L., & Wu, C. Y. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2002.12.002 · Cited by 256
Renes, J., De Vries, E. G. E., Nienhuis, E. F., Jansen, P. L. M., & Müller, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702360 · Cited by 256
Zeng, H., Chen, Z., Belinsky, M. G., Rea, P. A., & Kruh, G. D. (2001) · PubMed · Cited by 255
Zhao, R., & Goldman, I. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206946 · Cited by 253
Guo, Y., Kotova, E., Chen, Z.-S., Lee, K., Hopper-Borge, E., Belinsky, M. G., & Kruh, G. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304059200 · Cited by 253 · cited 1×
“Cells overexpressing MRP8 are resistant to commonly used purine and pyrimidine nucleotide analogue”
MethodSmith, A. J., van Helvoort, A., van Meer, G., Szabó, K., Welker, E., Szakács, G., Váradi, A., Sarkadi, B., & Borst, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909002199 · Cited by 252 · cited 1×
“, and MDR3 has been shown to promote the transcellular transport of several Pgp substrates, such as digoxin, paclitaxel and vinblastin”
BackgroundSelf-citationKoike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Volk, E. L., Farley, K. M., Wu, Y. F., Li, F., Robey, R. W., & Schneider, E. (2002) · PubMed · Cited by 248
Van Aubel, R. A. M. H., Smeets, P. H. E., van den Heuvel, J. J. M. W., & Russel, F. G. M. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00133.2004 · Cited by 246
Hepatic Secretion of Conjugated Drugs and Endogenous Substances
KEPPLER, D., & KÖNIG, J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9391 · Cited by 245
Pratt, S., Shepard, R. L., Kandasamy, R. A., Johnston, P. A., Perry, W., & Dantzig, A. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0291 · Cited by 245
Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H., Fukuda, M., Ikegami, Y., Sugahara, K., Yamada, Y., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4267 · Cited by 242 · cited 1×
“In addition, ABCG2 can transport some of the most recently developed anticancer drugs, such as 7-ethyl-10-hydroxycamptothecin (SN-38”
BackgroundExpression and Localization of Multidrug Resistant Protein mrp2 in Rat Small Intestine
Mottino, A. D., Hoffman, T., Jennes, L., & Vore, M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39291-2 · Cited by 239
Yamazaki, M., Neway, W. E., Ohe, T., Chen, I.-W., Rowe, J. F., Hochman, J. H., Chiba, M., & Lin, J. H. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38809-3 · Cited by 238
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
Qadir, M., O'Loughlin, K. L., Fricke, S. M., Williamson, N. A., Greco, W. R., Minderman, H., & Baer, M. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1725 · Cited by 236
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.048 · Cited by 235
Potschka, H., Fedrowitz, M., & Löscher, W. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049858 · Cited by 234
Itakura, J., Ishiwata, T., Shen, B., Kornmann, M., & Korc, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1<27::aid-ijc5>3.0.co;2-8 · Cited by 234
Breast cancer resistance protein (BCRP/ABCG2)
Staud, F., & Pavek, P. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.11.004 · Cited by 232
Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., BURT, M. E., & Scotto, K. W. (1999) · PubMed · Cited by 231
Venne, A., Li, S., Mandeville, R., Kabanov, A. V., & Alakhov, V. Y. (1996) · PubMed · Cited by 225
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
Bradshaw, D. M., & Arceci, R. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3674 · Cited by 223
Liu, J., Chen, H., Miller, D. S., Saavedra, J. E., Keefer, L. K., Johnson, D. R., Klaassen, C. D., & Waalkes, M. P. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23133-3 · Cited by 221
Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection
Morizono, K., Xie, Y., Ringpis, G.-E., Johnson, M., Nassanian, H., Lee, B., Wu, L., & Chen, I. S. Y. (2005) · Nature Medicine · doi:10.1038/nm1192 · Cited by 220
Young, L. C., Campling, B. G., Cole, S. P. C., Deeley, R. G., & Gerlach, J. H. (2001) · PubMed · Cited by 220
Transport Function and Hepatocellular Localization of mrp6 in Rat Liver
Madon, J., Hagenbuch, B., Landmann, L., Meier, P. J., & Stieger, B. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26431-2 · Cited by 218
Huisman, M. T., Chhatta, A. A., van Tellingen, O., Beijnen, J. H., & Schinkel, A. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21013 · Cited by 211
Hegedűs, T., Őrfi, L., Seprődi, A., Váradi, A., Sarkadi, B., & Kéri, G. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00095-9 · Cited by 207
Evers, R., Kool, M., Smith, A. J., Deemter, L. V., de Haas, M., & Borst, P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1260 · Cited by 206
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205
Cyclosporins as drug resistance modifiers
Twentyman, P. R. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90668-9 · Cited by 201
Ros, J. E., Libbrecht, L., Geuken, M., Jansen, P. L., & Roskams, T. A. (2003) · The Journal of Pathology · doi:10.1002/path.1379 · Cited by 198
Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10)
Hopper-Borge, E., Chen, Z.-S., Shchaveleva, I., Belinsky, M. G., & Kruh, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3111 · Cited by 198 · cited 1×
“Studies indicate that MRP6-transfected cells become resistant to natural product agents, including etoposide, teniposide, doxorubicin and daunorubicin, whereas MRP7 is a resistance factor for taxane”
BackgroundVail, D. M., Amantea, M. A., Colbern, G. T., Martin, F. J., Hilger, R. A., & Working, P. K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.002 · Cited by 187 · cited 1×
“Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (PLD) might be safer and occasionally more effective than conventional doxorubici”
BackgroundZelcer, N., Wetering, K. V. D., Waart, R. D., Scheffer, G. L., Marschall, H.-U., Wielinga, P. R., Kuil, A., Kunne, C., Smith, A., Valk, M. V. D., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.07.022 · Cited by 181 · cited 1×
“However, recent analysis of mrp3 -deficient mice has not revealed any abnormalities in bile acid homeostasis, indicating that Mrp3 does not have a key role in bile salt physiolog”
BackgroundChen, Z.-S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M., & Akiyama, S.-I. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1219 · Cited by 178
Role of MRP2 and GSH in intrahepatic cycling of toxins
Dietrich, C. (2001) · Toxicology · doi:10.1016/s0300-483x(01)00459-0 · Cited by 177
Zhang, Y., Schuetz, J. D., Elmquist, W. F., & Miller, D. W. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068528 · Cited by 175
Cancer multidrug resistance: a review of recent drug discovery research.
Liscovitch, M., & Lavie, Y. (2002) · PubMed · Cited by 170
Minderman, H., O’Loughlin, K. L., Pendyala, L., & Baer, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0914-3 · Cited by 170 · cited 1×
“Biricodar (VX-710) and GF-120918, for example, bind Pgp as well as MRP1 and ABCG2, respectivel”
Backgroundvan der Holt, B. (2005) · Blood · doi:10.1182/blood-2005-04-1395 · Cited by 169 · cited 1×
“Pgp expression in patients with AML has consistently been associated with reduced chemotherapy response rates and poor survival, and it was found to be an independent prognostic variable for induction failure in adult AM”
BackgroundAnalysis of the In Vivo Functions of Mrp3
Belinsky, M. G., Dawson, P. A., Shchaveleva, I., Bain, L. J., Wang, R., Ling, V., Chen, Z.-S., Grinberg, A., Westphal, H., Klein-Szanto, A., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010587 · Cited by 168 · cited 1×
“However, recent analysis of mrp3 -deficient mice has not revealed any abnormalities in bile acid homeostasis, indicating that Mrp3 does not have a key role in bile salt physiolog”
BackgroundClinical Relevance of P-Glycoprotein in Drug Therapy
Lin, J. H., & Yamazaki, M. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026871 · Cited by 167
Multidrug resistance related molecules in human and murine lung
Scheffer, G. L., Pijnenborg, A. C. L. M., Smit, E. F., Muller, M., Postma, D. S., Timens, W., van der Valk, P., de Vries, E. G. E., & Scheper, R. J. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.5.332 · Cited by 165
Chu, X.-Y., Kato, Y., Niinuma, K., Sudo, K.-I., Hakusui, H., & Sugiyama, Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36601-7 · Cited by 161
Mahadevan, D., & List, A. F. (2004) · Blood · doi:10.1182/blood-2003-07-2490 · Cited by 161 · cited 1×
“Indeed, it could well be that the benefit of classical inhibitors was derived solely from the augmented dose intensity of the concomitantly administered chemotherapeutics, as opposed to the pharmacodynamic modulation of target cell”
BackgroundDalton, W. S., Crowley, J. J., Salmon, S., Grogan, T. M., Laufman, L. R., Weiss, G. R., & Bonnet, J. D. (1995) · Cancer · doi:10.1002/1097-0142(19950201)75:3<865::aid-cncr2820750319>3.0.co;2-z · Cited by 157
Wielinga, P. R., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., van der Born, K., de Haas, M., van der Heijden, I., Kaspers, G. J. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2810 · Cited by 156
Russo, C. L., Pellarin, M., Tingby, O., Bollen, A. W., Lamborn, K. R., Mohapatra, G., Collins, V. P., & Feuerstein, B. G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<316::aid-cncr16>3.0.co;2-t · Cited by 153
Considerations in the design and development of transport inhibitors as adjuncts to drug therapy
Dantzig, A. H., de Alwis, D. P., & Burgess, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00175-8 · Cited by 152 · cited 1×
“Nevertheless, modulators are unlikely to improve the therapeutic index of anticancer drugs unless agents that lack significant pharmacokinetic interactions are foun”
BackgroundKolitz, J. E., George, S. L., Dodge, R. K., Hurd, D. D., Powell, B. L., Allen, S. L., Vélez-García, E., Moore, J. O., Shea, T. C., Hoke, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.106 · Cited by 150 · cited 1×
“A subsequent dose-escalation trial involving 410 patients with AML who were”
BackgroundMechanisms of multidrug resistance in HL60 cells
McGrath, T., Diaz‐Latoud, C., Arnold, S. T., Safa, A. R., Felsted, R. L., & M S Center (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90134-2 · Cited by 150
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.
FitzGerald, D. J., Willingham, M. C., CARDARELLI, C. O., Hamada, H., TSURUO, T., Gottesman, M. M., & PASTAN, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.12.4288 · Cited by 148
Self-citationTyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Özvegy-Laczka, C., Cserepes, J., Elkind, N. B., & Sarkadi, B. (2005) · Drug resistance updates · doi:10.1016/j.drup.2005.02.002 · Cited by 144
Lepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D., & Sparreboom, A. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.2.115 · Cited by 142
Berger, W., Setinek, U., Hollaus, P. H., Zidek, T., Steiner, E., Elbling, L., Cantonati, H., Attems, J., Gsur, A., & Micksche, M. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0653-9 · Cited by 142 · cited 1×
“, and its prognostic implication in chronic lymphocytic and promyelocytic leukaemia, non-small-cell lung cancer (NSCLC) and breast cancer remains controversia”
BackgroundWang, X., Furukawa, T., Nitanda, T., Okamoto, M., Sugimoto, Y., Akiyama, S.-I., & Baba, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.65 · Cited by 142
Peng, K., Cluzeaud, F., Bens, M., van Huyen, J. D., Wioland, M., Lacave, R., & Vandewalle, A. (1999) · Journal of Histochemistry and Cytochemistry · doi:10.1177/002215549904700605 · Cited by 142
Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein.
Childs, S. J., Yeh, R. L., Hui, D., & Ling, V. W. T. (1998) · PubMed · Cited by 141
Melaine, N., Liénard, M.-O., Dorval, I., Goascogne, C. L., Lejeune, H., & Jégou, B. (2002) · Biology of Reproduction · doi:10.1095/biolreprod.102.003558 · Cited by 141
Role of MRP4 and MRP5 in biology and chemotherapy
Sampath, J., Adachi, M., Hatse, S., Naesens, L. M. J., Balzarini, J. M., Flatley, R. M., Matherly, L. H., & Schuetz, J. D. (2002) · AAPS PharmSci · doi:10.1208/ps040314 · Cited by 139
Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979
Shepard, R. L., Cao, J., Starling, J. J., & Dantzig, A. H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10792 · Cited by 138
Norris, M. D., Smith, J. L., Tanabe, K. M., Tobin, P. J., Flemming, C. L., Scheffer, G. L., Wielinga, P. R., Cohn, S. L., London, W. B., Marshall, G. M., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0161 · Cited by 138
Agrawal, M., Abraham, J., Balis, F. M., Edgerly, M., Stein, W. D., Bates, S. E., Fojo, T., & Chen, C. C. (2003) · PubMed · Cited by 135
Chen, Z., Guo, Y., Belinsky, M. G., Kotova, E., & Kruh, G. D. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007138 · Cited by 135 · cited 1×
“In addition, MRP8 is thought to participate in physiological processes involving bile acids and conjugated steroid”
BackgroundBöhme, M., Büchler, M., Müller, M., & Keppler, D. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80403-h · Cited by 132
Höll, V., Kouba, M., Dietel, M., & Vogt, G. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90149-d · Cited by 131 · cited 1×
“For example, the R -enantiomer of verapamil and the cyclosporin D analogue PSC-833 (Valspodar) antagonized Pgp function without blocking calcium channels or immunosuppressive effects, respectivel”
BackgroundGermann, U. A., Ford, P. J., Shlyakhter, D., Mason, V. S., & Harding, M. W. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199702000-00005 · Cited by 131
Liedert, B., Materna, V., Schadendorf, D., Thomale, J., & Lage, H. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12313.x · Cited by 129 · cited 1×
“Cells selected in cisplatin, arsenite or 9-nitro-camptothecin show increased MRP2 expressio”
BackgroundAllen, J. D., Dort, S. C. V., Buitelaar, M., van Tellingen, O., & Schinkel, A. H. (2003) · PubMed · Cited by 129
Co-administration of cyclosporin enables oral therapy with paclitaxel
Terwogt, J. M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., & Schellens, J. H. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24030-x · Cited by 129
Lecureur, V., Sun, D., Hargrove, P., Schuetz, E. G., Kim, R. B., Lan, L.-B., & Schuetz, J. D. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26438-5 · Cited by 128
Trompier, D., Chang, X.-B., Barattin, R., d′Hardemare, A. D. M., Pietro, A. D., & Baubichon-Cortay, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0143 · Cited by 127
Stewart, A. J., Steiner, J., MELLOWS, G., Laguda, B., Norris, D., & Bevan, P. (2000) · PubMed · Cited by 122
Williams, G. C., Liu, A., Knipp, G., & Sinko, P. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3456-3462.2002 · Cited by 122
Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers
Gao, Z., Fain, H. D., & Rapoport, N. (2004) · Molecular Pharmaceutics · doi:10.1021/mp049958h · Cited by 121 · cited 1×
“To trigger drug release, the tumour is irradiated with ultrasoun”
MethodFilipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C. C., Hausmaninger, H., Kubista, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.033 · Cited by 120 · cited 1×
“, and its prognostic implication in chronic lymphocytic and promyelocytic leukaemia, non-small-cell lung cancer (NSCLC) and breast cancer remains controversia”
BackgroundHuman Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins
Tian, Q., Zhang, J., Tan, T. M. C., Chan, E., Duan, W., Chan, S. Y., Boelsterli, U. A., Ho, P. C., Yang, H., Bian, J., et al. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-7595-z · Cited by 119
Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer
Atkinson, D. E., Greenwood, S. L., Sibley, C. P., Glazier, J. D., & Fairbairn, L. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00418.2002 · Cited by 118
Multidrug Resistance: Can New Drugs Help Chemotherapy Score Against Cancer?
Goldman, B. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.255 · Cited by 118 · cited 1×
“Similarly, development of another second-generation inhibitor showing initial promise (VX-710; biricodar) has been curtaile”
BackgroundBelpomme, D., Gauthier, S., Pujade-Lauraine, É., Facchini, T., Goudier, M.-J., Krakowski, I., Netter-Pinon, G., Frénay, M., Gousset, C., MARIE, F.-N., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026556119020 · Cited by 118
McGrath, T., & M S Center (1988) · PubMed · Cited by 117
Luo, F., Paranjpe, P. V., Guo, A., Rubin, E. H., & Sinko, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.763 · Cited by 116
Morrow, C. S., Peklak-Scott, C., Bishwokarma, B., Kute, T. E., Smitherman, P. K., & Townsend, A. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017988 · Cited by 116
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
Yang, C.-H., Schneider, E., Kuo, M., Volk, E. L., Rocchi, E., & Chen, Y. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00396-8 · Cited by 113
Solary, É., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.-Y. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1198.bloodjournal8841198 · Cited by 109
Blockage of Drug Resistance In Vitro by Disulfiram, a Drug Used to Treat Alcoholism
Loo, T. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.898 · Cited by 107 · cited 1×
“Similar to their predecessors, some of the emerging candidates are 'off the shelf' compounds (old drugs with new tricks), such as disulfiram, used to treat alcoholis”
BackgroundVulevic, B., Chen, Z., Boyd, J. T., Davis, W., Walsh, E. S., Belinsky, M. G., & Tew, K. D. (2001) · PubMed · Cited by 107
Sharom, F. J., Yu, X., Lu, P., Liu, R., Chu, J. W. K., Szabó, K., Müller, M., Hose, C. D., Monks, A. P., Váradi, A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00139-2 · Cited by 107
Raaijmakers, M. H. G. P., de Grouw, E. P. L. M., Heuver, L. H. H., van der Reijden, B. A., Jansen, J. H., Scheper, R. J., Scheffer, G. L., de Witte, T. J. M., & Raymakers, R. A. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0212 · Cited by 106 · cited 1×
“Although ABCG2 is expressed in leukaemic CD34 + 38 − stem cells, its functional relevance seems limite”
BackgroundWishart, G. C., Bissett, D., Paul, J., Jodrell, D. I., Harnett, A. N., Habeshaw, T., Kerr, D. J., Macham, M. A., Soukop, M., & Leonard, R. C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1771 · Cited by 102
van Zuylen, L., Sparreboom, A., van der Gaast, A., van der Burg, M. E., van Beurden, V., Bol, C. J., Woestenborghs, R., Palmer, P. A., & Verweij, J. (2000) · PubMed · Cited by 101
Sauna, Z. E., Peng, X.-H., Nandigama, K., Tekle, S., & Ambudkar, S. V. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.675 · Cited by 100
Yin, J. A. L., Wheatley, K., Rees, J. K. H., Burnett, A. K., & Party, T. U. M. A. L. W. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02785.x · Cited by 100
Sugiyama, D., Kusuhara, H., Lee, Y. J., & Sugiyama, Y. (2003) · Pharmaceutical Research · doi:10.1023/a:1025749925541 · Cited by 99
Mizuno, N., Suzuki, M., Kusuhara, H., Suzuki, H., Takeuchi, K., Niwa, T., Jonker, J. W., & Sugiyama, Y. (2004) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)02969-6 · Cited by 99
In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein
Pichler, A., Zelcer, N., Prior, J. L., Kuil, A., & Piwnica-Worms, D. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0038 · Cited by 97 · cited 1×
“Sufficient downregulation of Pgp has proved difficult to attain and the safe delivery of constructs to cancer cells in vivo remains a challeng”
BackgroundBartsevich, V. V., & Juliano, R. L. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.1.1 · Cited by 96
Solary, É., Drénou, B., Campos, L., de Crémoux, P., Mugneret, F., Moreau, P., Lioure, B., Falkenrodt, A., Witz, B., Bernard, M., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3419 · Cited by 96
Sonneveld, P., Suciu, S., Weijermans, P., Beksac, M., Neuwirtova, R., Solbu, G., Lokhorst, H., Van Der Lelie, J., Dohner, H., Gerhartz, H., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03171.x · Cited by 93
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
Millward, M., Cantwell, B., Munro, N., Robinson, A., Corris, P., & Harris, A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.189 · Cited by 91
Chu, X., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., et al. (1998) · PubMed · Cited by 90
Yang, J. C., Horton, J. K., Cowan, K. H., & Schneider, E. (1995) · PubMed · Cited by 89
Involvement of MDR1 P‐glycoprotein in multifactorial resistance to methotrexate
Norris, M. D., de Graaf, D., Haber, M., Kavallaris, M., Madafiglio, J., Gilbert, J., Kwan, E., Stewart, B. W., Mechetner, E. B., Gudkov, A. V., et al. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960301)65:5<613::aid-ijc10>3.0.co;2-8 · Cited by 89
Cellular localization and functional expression of P‐glycoprotein in rat astrocyte cultures
Ronaldson, P. T., Bendayan, M., Gingras, D., Piquette‐Miller, M., & Bendayan, R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02417.x · Cited by 89
Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions
Tarasova, N. I., Rice, W. G., & Michejda, C. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34911 · Cited by 88 · cited 1×
“Peptide analogues of TMDs are believed to interfere with the proper assembly or function of the target protein, as was shown in experiments aimed at the in vitro”
Background
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
“, glutathione S-transferase) or resistance to apoptosis/senescence pathways [239-242].”
BackgroundKamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.